75y.o.q5yhormonetherapy40y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorq1-2ymammogrambased on lifeexpectancy /health statusTimedup andgo test3%2 doses,2-6monthsapartq1y≥ 140mg/dLcervicalcancerFractureRiskAssessmentTool52y.o.q3yaromataseinhibitors40-70 y.o.,ASCVD ≥10%, lowbleeding risk≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 126mg/dL65y.o.cardiovasculardiseasecolorectalcancerwomenage 55-64 y.o.raloxifenedyslipidemiatobaccouseovariancancer40-59 y.o.,ASCVD ≥10%, lowbleeding risklungcancer≥6.5%≥5.7%Gailmodelinsufficientevidenceforscreening40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsstatinHIVanxiety40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor≥ 100mg/dL50y.o.1 dose; 2doses (2-6monthsapart) ifimmunocompHepatitisCdepression< 60y.o.hypertensionbreastcancermultidoseinitial series,then 1 doseat 2-6monthsTyrer-Cuzickmodelq1ymammogram≥20%PREVENTequationaspirin60y.o.diabetesdementiaoverweight/ obesityq15yHepatitisBpneumococcal≥ 200mg/dLq2ycommunity-dwelling,postmenopausalwomenherpeszostertamoxifen≤q2y75y.o.q5yhormonetherapy40y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorq1-2ymammogrambased on lifeexpectancy /health statusTimedup andgo test3%2 doses,2-6monthsapartq1y≥ 140mg/dLcervicalcancerFractureRiskAssessmentTool52y.o.q3yaromataseinhibitors40-70 y.o.,ASCVD ≥10%, lowbleeding risk≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 126mg/dL65y.o.cardiovasculardiseasecolorectalcancerwomenage 55-64 y.o.raloxifenedyslipidemiatobaccouseovariancancer40-59 y.o.,ASCVD ≥10%, lowbleeding risklungcancer≥6.5%≥5.7%Gailmodelinsufficientevidenceforscreening40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsstatinHIVanxiety40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factor≥ 100mg/dL50y.o.1 dose; 2doses (2-6monthsapart) ifimmunocompHepatitisCdepression< 60y.o.hypertensionbreastcancermultidoseinitial series,then 1 doseat 2-6monthsTyrer-Cuzickmodelq1ymammogram≥20%PREVENTequationaspirin60y.o.diabetesdementiaoverweight/ obesityq15yHepatitisBpneumococcal≥ 200mg/dLq2ycommunity-dwelling,postmenopausalwomenherpeszostertamoxifen≤q2y

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. 75 y.o.
  2. q5y
  3. hormone therapy
  4. 40 y.o.
  5. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  6. q1-2y mammogram based on life expectancy / health status
  7. Timed up and go test
  8. 3%
  9. 2 doses, 2-6 months apart
  10. q1y
  11. ≥ 140 mg/dL
  12. cervical cancer
  13. Fracture Risk Assessment Tool
  14. 52 y.o.
  15. q3y
  16. aromatase inhibitors
  17. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  18. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  19. ≥ 126 mg/dL
  20. 65 y.o.
  21. cardiovascular disease
  22. colorectal cancer
  23. women age 55-64 y.o.
  24. raloxifene
  25. dyslipidemia
  26. tobacco use
  27. ovarian cancer
  28. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  29. lung cancer
  30. ≥ 6.5%
  31. ≥ 5.7%
  32. Gail model
  33. insufficient evidence for screening
  34. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  35. statin
  36. HIV
  37. anxiety
  38. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  39. ≥ 100 mg/dL
  40. 50 y.o.
  41. 1 dose; 2 doses (2-6 months apart) if immunocomp
  42. Hepatitis C
  43. depression
  44. < 60 y.o.
  45. hypertension
  46. breast cancer
  47. multidose initial series, then 1 dose at 2-6 months
  48. Tyrer-Cuzick model
  49. q1y mammogram
  50. ≥ 20%
  51. PREVENT equation
  52. aspirin
  53. 60 y.o.
  54. diabetes
  55. dementia
  56. overweight / obesity
  57. q15y
  58. Hepatitis B
  59. pneumococcal
  60. ≥ 200 mg/dL
  61. q2y
  62. community-dwelling, postmenopausal women
  63. herpes zoster
  64. tamoxifen
  65. ≤ q2y